NCI SBIR Concept Award Transition to Phase II FY2027 (BAA)
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $3,000,000 to $7,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
-
- Kathleen Sears kathleen.sears@nih.gov
- william.bozza@nih.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health forecasts a new requirement for the NCI SBIR Innovative Concept Award Transition to Phase II FY2027 (BAA), with an estimated award date of 2027-04-01 and an estimated solicitation release date of 2026-06-01. The program funds R&D contracts that advance early-stage, high-risk technologies for rare and pediatric cancers from Phase I Concept Award completion through later-stage product development toward clinical investigation and commercialization. Eligibility is restricted to offerors that successfully completed a Phase I Concept Award under this program, and the set-aside is Total Small Business.
The estimated award value range is $3 million to $7 million, and the NAICS code is 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). Kathleen Sears (kathleen.sears@nih.gov) and William Bozza, Program Director (william.bozza@nih.gov, (240) 660-1211), are the listed points of contact.
Forecast text
The Concept Award is designed to emphasize innovation and support small businesses that are developing early-stage game changer technologies for rare and pediatric cancers through research and development (R&D) contracts. Initially, small businesses can apply for Phase I funding up to $300,000. Traditional Phase I SBIR applications rarely get funded without substantial preliminary data and as a result innovative but high-risk projects tend to not review well. Therefore, disruptive technologies that are early-stage and high-risk are underrepresented in the NCI SBIR portfolio. Also underrepresented in the portfolio are technologies in the rare and pediatric cancer space, which are often overlooked by small businesses due to market size, development risk, and small patient cohorts. By focusing the Concept Award on these areas (high innovation, no preliminary data, and rare/pediatric cancers), NCI aims to increase small business support for early-stage technologies with significant potential for transformative patient impact.
This NCI SBIR Innovative Concept Award Transition to Phase II solicitation is intended to further support NCI funded Phase I Concept Award technologies through later stage product development toward clinical investigation and commercialization through $3M R&D contracts. Eligibility for Phase II funding is restricted to Offerors who have successfully completed a Phase I Concept Award under this program.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast